ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Tevogen Bio Holdings Inc.
0.0379
-0.0054
-12.47%
成交量:
36.61萬
成交額:
1.35萬
市值:
745.51萬
市盈率:
-0.18
高:
0.0426
開:
0.0426
低:
0.0253
收:
0.0433
52周最高:
0.0800
52周最低:
0.0253
股本:
1.97億
流通股本:
1.97億
量比:
4.54
換手率:
0.19%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.2138
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
Tevogen Bio Holdings簽署意向書 擬評估收購Sciometrix及其數字護理管理平台Clinicus
美股速递
·
02/26
Tevogen Bio Holdings Inc.盤中異動 股價大漲6.06%報0.294美元
市场透视
·
02/20
Tevogen Bio Holdings Inc.盤中異動 早盤股價大跌5.20%報0.332美元
市场透视
·
01/26
Tevogen Bio Holdings Inc.盤中異動 快速上漲6.10%報0.411美元
市场透视
·
2025/11/18
Tevogen宣佈重大臨床里程碑:擴展其針對急性和長期新冠的精準T細胞治療的HLA覆蓋範圍
美股速递
·
2025/11/06
Tevogen Bio Holdings Inc.盤中異動 下午盤急速跳水5.44%
市场透视
·
2025/11/05
Tevogen Bio Holdings Inc.盤中異動 快速下挫5.39%
市场透视
·
2025/10/03
Tevogen Bio Holdings Inc - TVGN 116項目未來5年累計營收預測約65億美元
美股速递
·
2025/09/10
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TVGNW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGNW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings Inc.","latestPrice":0.0379,"timestamp":1772658000000,"preClose":0.0433,"halted":0,"volume":366132,"delay":0,"changeRate":-0.12471131639722853,"floatShares":196705066,"shares":196705066,"eps":-0.2138,"marketStatus":"未開盤","change":-0.0054,"latestTime":"03-04 16:00:00 EST","open":0.0426,"high":0.0426,"low":0.0253,"amount":13483.536721,"amplitude":0.399538,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.2138,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1772701200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0433,"volumeRatio":4.537998},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","floatShares":196705066,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.537998,"shares":196705066,"dividePrice":0,"high":0.0426,"amplitude":0.399538,"preClose":0.0433,"low":0.0253,"week52Low":0.0253,"pbRate":"--","week52High":0.08,"institutionHeld":0,"latestPrice":0.0379,"eps":-0.2138,"divideRate":0,"volume":366132,"delay":0,"ttmEps":-0.2138,"open":0.0426,"prevYearClose":0.0422,"prevWeekClose":0.0448,"prevMonthClose":0.0448,"prevQuarterClose":0.0422,"fiveDayClose":0.0426,"twentyDayClose":0.0444,"sixtyDayClose":0.0445},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGNW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGNW","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGNW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGNW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGNW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1106152731","title":"Tevogen Bio Holdings簽署意向書 擬評估收購Sciometrix及其數字護理管理平台Clinicus","url":"https://stock-news.laohu8.com/highlight/detail?id=1106152731","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106152731?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115616,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings已签署意向书,正就潜在收购医疗科技公司Sciometrix及其创新数字护理管理平台Clinicus展开评估。此次战略举措旨在整合Clinicus的智能化患者管理技术,强化Tevogen在精准医疗领域的数字化服务能力。\n该平台通过人工智能驱动的远程监测系统,可实现个性化治疗方案的动态优化。若交易顺利完成,将显著提升Tevogen在细胞疗法商业化过程中的患者全周期管理效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2612259751","title":"Tevogen Bio Holdings Inc.盤中異動 股價大漲6.06%報0.294美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612259751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612259751?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 00:20","pubTimestamp":1771518007,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日00时20分,Tevogen Bio Holdings Inc.股票出现异动,股价大幅拉升6.06%。截至发稿,该股报0.294美元/股,成交量26.4044万股,换手率0.13%,振幅5.38%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中,整体跌幅为0.39%。Tevogen Bio Holdings Inc.公司简介:Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司,利用CD8细胞毒性T淋巴细胞,开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220002007a4b3d280&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220002007a4b3d280&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2606786226","title":"Tevogen Bio Holdings Inc.盤中異動 早盤股價大跌5.20%報0.332美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786226","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606786226?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 23:58","pubTimestamp":1769443133,"startTime":"0","endTime":"0","summary":"北京时间2026年01月26日23时58分,Tevogen Bio Holdings Inc.股票出现异动,股价大幅跳水5.20%。截至发稿,该股报0.332美元/股,成交量7.9391万股,换手率0.04%,振幅4.77%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中,整体涨幅为0.49%。Tevogen Bio Holdings Inc.公司简介:Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司,利用CD8细胞毒性T淋巴细胞,开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126235853a6af01f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126235853a6af01f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2584941954","title":"Tevogen Bio Holdings Inc.盤中異動 快速上漲6.10%報0.411美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941954?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 22:34","pubTimestamp":1763476478,"startTime":"0","endTime":"0","summary":"北京时间2025年11月18日22时34分,Tevogen Bio Holdings Inc.股票出现波动,股价急速上涨6.10%。截至发稿,该股报0.411美元/股,成交量5.7367万股,换手率0.03%,振幅3.95%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中,整体跌幅为0.20%。Tevogen Bio Holdings Inc.公司简介:Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司,利用CD8细胞毒性T淋巴细胞,开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118223438a70225ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118223438a70225ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"1141099932","title":"Tevogen宣佈重大臨床里程碑:擴展其針對急性和長期新冠的精準T細胞治療的HLA覆蓋範圍","url":"https://stock-news.laohu8.com/highlight/detail?id=1141099932","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141099932?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 04:20","pubTimestamp":1762374032,"startTime":"0","endTime":"0","summary":"Tevogen宣布重大临床里程碑:扩展其针对急性和长期新冠的精准T细胞治疗的HLA覆盖范围","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2581834794","title":"Tevogen Bio Holdings Inc.盤中異動 下午盤急速跳水5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581834794","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581834794?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 03:09","pubTimestamp":1762283362,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日03时09分,Tevogen Bio Holdings Inc.股票出现波动,股价快速下跌5.44%。截至发稿,该股报0.556美元/股,成交量26.711万股,换手率0.14%,振幅5.71%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中,整体跌幅为0.03%。Tevogen Bio Holdings Inc.公司简介:Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司,利用CD8细胞毒性T淋巴细胞,开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110503092297540342&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110503092297540342&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2572665597","title":"Tevogen Bio Holdings Inc.盤中異動 快速下挫5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572665597","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572665597?lang=zh_tw&edition=fundamental","pubTime":"2025-10-03 22:08","pubTimestamp":1759500498,"startTime":"0","endTime":"0","summary":"北京时间2025年10月03日22时08分,Tevogen Bio Holdings Inc.股票出现异动,股价急速下跌5.39%。截至发稿,该股报0.737美元/股,成交量15.9692万股,换手率0.08%,振幅6.16%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中,整体涨幅为0.05%。Tevogen Bio Holdings Inc.公司简介:Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司,利用CD8细胞毒性T淋巴细胞,开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003220818a4526c16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003220818a4526c16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"1153465336","title":"Tevogen Bio Holdings Inc - TVGN 116項目未來5年累計營收預測約65億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153465336","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153465336?lang=zh_tw&edition=fundamental","pubTime":"2025-09-10 03:18","pubTimestamp":1757445502,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc - TVGN 116项目未来5年累计营收预测约65亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}